myWave

European network for advancing Electromagnetic hyperthermic medical technologies (2017 - 2021)

Electromagnetic (EM) hyperthermic technologies hold great potential in the treatment of diseases, especially for cancers that are resistant to standard regimens. These technologies modify tissue temperature: hyperthermia heats the diseased tissue to make it susceptible to treatments, and ablation heats the tissue until it is destroyed. Hyperthermia is particularly effective in treatment of cervical and breast cancer, head and neck cancers, sarcoma in adults, and germ cell tumours in children; while radiofrequency and microwave ablation offer promise for treating liver, kidney, and lung cancers.

MyWAVE  is establishing an inter-disciplinary network that brings together key players in the engineering and physical sciences, clinicians as well as translational researchers with a common aim to advance the design, development and commercialisation of electromagnetic hyperthermic technologies.

Electromagnetic (EM) hyperthermic technologies hold great potential in the treatment of diseases, especially for cancers that are resistant to standard regimens. These technologies modify tissue temperature: hyperthermia heats the diseased tissue to make it susceptible to treatments, and ablation heats the tissue until it is destroyed. Hyperthermia is particularly effective in treatment of cervical and breast cancer, head and neck cancers, sarcoma in adults, and germ cell tumours in children; while radiofrequency and microwave ablation offer promise for treating liver, kidney, and lung cancers.